23.3 C
New York
Thursday, September 23, 2021

WHAT is happening with CNS Pharmaceuticals Inc. (CNSP) stock?

CNS Pharmaceuticals Inc. (CNSP) stock face both trends on Thursday, March 18, 2021. It gained 5.65% in the normal trading session but lost 6.02% in the extended trading session. Still, there is no recent development supporting its loss and gains.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Let’s have a look at the recent news of CNSP.

Participation in Inaugural Emerging Growth Virtual Conference

CNSP participated in the Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC which took place virtually on March 17th and 18th. The company was represented by CNSP CEO John Climaco.

Participation in H.C. Wainwright Global Life Sciences Conference

The CNSPharmaceuticals also participated in H.C. Wainwright Global Life Sciences Conference which took place virtually on March 9-10, 2021.CEO John Climaco presented the company.

Commencing of Berubicin Trial

On February 25, 2021, the CNSP announced thatthe clinical program for Berubicin will start enrolling patients in March 2021.

Berubicin is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of several serious brain and CNS oncology indications.

Berubicin Supply Agreement with WPD Pharmaceuticals

On February 24, 2021, WPD Pharmaceuticals signed an agreement with CNSP to obtain an Investigational Medicinal Product for use in the planned clinical trials of Berubicin.

According to the agreement, half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies will be purchased by the WPD.

About the Company

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. CNS holds a worldwide exclusive license to the Berubicin chemical compound which is proposed for the treatment of glioblastoma multiforme.

John M. Climaco, Esq. is the CEO of CNS Pharmaceuticals. He has 15 years of experience in different leadership roles in different healthcare companies.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.